SLC2A2: A Potential Drug Target and Biomarker (G6514)

Target Name: SLC2A2

NCBI ID: G6514

SLC2A2

SLC2A2: A Potential Drug Target and Biomarker

SLC2A2 (Sodium Chloride Transporter 2A2) is a protein that is expressed in most tissues of the body and plays a critical role in the transport of sodium chloride (NaCl) across cell membranes. It is a member of the SLC transporter family, which includes six different isoforms (SLC1, SLC2, SLC3, SLC4, SLC5, and SLC6) that are responsible for transporting various electrolytes across cell membranes. SLC2A2 is the most abundant isoform in the human body and is expressed in most tissues, including the brain, heart, liver, kidney, and pancreas.

SLC2A2 is a transmembrane protein that consists of a catalytic active region, a regulatory region, and an optional cytoplasmic region. The catalytic active region is responsible for the actual transport of sodium chloride across the membrane, while the regulatory region is responsible for regulating the transport process. The cytoplasmic region is not involved in the transport process.

SLC2A2 is expressed in most tissues of the body and is involved in the regulation of a wide range of physiological processes that are dependent on the proper functioning of sodium chloride. For example, it is involved in the regulation of water and electrolyte balance, as well as the regulation of blood pressure. It is also involved in the regulation of the extracellular matrix (ECM), which is a complex tissue matrix that is responsible for providing support and structure to various tissues and organs.

SLC2A2 is a potential drug target for several diseases, including hypertension, heart failure, and neurodegenerative diseases. One of the main reasons for its potential as a drug target is its involvement in the regulation of physiological processes that are important for human health. For example, SLC2A2 is involved in the regulation of water and electrolyte balance, which is important for maintaining the proper functioning of the body's cells and tissues. It is also involved in the regulation of blood pressure, which is important for maintaining the proper functioning of the cardiovascular system.

Another reason for SLC2A2's potential as a drug target is its involvement in the regulation of the extracellular matrix. ECM is a complex tissue matrix that is responsible for providing support and structure to various tissues and organs. SLC2A2 is involved in the regulation of ECM formation and is thought to play a role in the development and progression of various diseases, including cancer.

SLC2A2 is also a potential biomarker for several diseases, including hypertension, heart failure, and neurodegenerative diseases. For example, SLC2A2 levels have been shown to be elevated in individuals with hypertension and heart failure, which suggests that they may be at increased risk for these diseases. SLC2A2 levels have also been shown to be elevated in individuals with certain neurodegenerative diseases, which suggests that these diseases may be caused by changes in SLC2A2 function.

Despite its potential as a drug target and biomarker, SLC2A2 is not yet widely studied. There are currently no drugs that are specifically designed to target SLC2A2, and research is focused on understanding its function and the potential mechanisms that regulate its activity. However, studies using other transmembrane proteins that are similar to SLC2A2 have shown that they are involved in the regulation of various physiological processes, including the regulation of ion channels and the regulation of protein transport.

In conclusion, SLC2A2 is a transmembrane protein that is involved in the regulation of various physiological processes that are important for human health. As a potential drug target and biomarker, SLC2A2 is thought to be involved in the regulation of water and electrolyte balance, blood pressure, and the regulation of the extracellular matrix. Further research is needed to understand its full function and the potential mechanisms that regulate its activity.

Protein Name: Solute Carrier Family 2 Member 2

Functions: Facilitative hexose transporter that mediates the transport of glucose, fructose and galactose (PubMed:8027028, PubMed:16186102, PubMed:23396969, PubMed:28083649, PubMed:8457197). Likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell (PubMed:8027028). May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney (PubMed:3399500). Also able to mediate the transport of dehydroascorbate (PubMed:23396969)

The "SLC2A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets